Table 2.
Oparil et al 2001 | Brunner et al 2003 | |||||
---|---|---|---|---|---|---|
Olmesartan medoxomil | Losartan | Valsartan | Irbesartan | Olmesartan medoxomil | Candesartan cilexetil | |
20 mg (n=145) | 50 mg (n=146) | 80 mg (n=142) | 150 mg (n=145) | 20 mg (n=312) | 8 mg (n=323) | |
Cuff measurements | ||||||
DBPa | 11.5 | 8.2*** | 7.9*** | 9.9* | 15.8 | 15.1 |
SBP | 11.3 | 9.5 | 8.4 | 11.0 | 21.2 | 21.1 |
Ambulatory measurements | ||||||
24 h | ||||||
DBP | 8.5 | 6.2* | 5.6* | 7.4* | 9.1 | 7.7* |
SBP | 12.5 | 9.0* | 8.1* | 11.3 | 12.7 | 11.0 |
Day | ||||||
DBPb | 10.2 | 7.2** | 7.0*** | 8.8 | 9.3 | 7.8* |
SBP | 14.7 | 10.9** | 10.2** | 13.8 | 13.0 | 11.1* |
Night | ||||||
DBP | 6.8 | 5.2 | 4.2** | 5.9 | 7.9 | 6.7 |
SBP | 10.3 | 7.3* | 6.1** | 8.8 | 10.9 | 9.7 |
Note: Primary endpoint in the trial by Oparil et al (2001);
Primary endpoint in the trial by Brunner et al (2003);
p≤0.05;
p≤0.005;
p≤0.0005 vs olmesartan medoxomil.